Institut Catala d'Oncologia l'Hospitalet

Barcelona 8908

6 studies enrolling now · 16 studies all time

What they study most

ALK-Positive Large B-Cell Lymphoma, Acute GVHD, Acute-graft-versus-host Disease, Advanced Cancer, Advanced Gastrointestinal Stromal Tumors, Advanced Solid Tumor, Advanced Solid Tumor Historically Known for High EphA2 Expression, B-cell Lymphoma, BMM, Bone Marrow Mastocytosis, Brain Tumor, Burkitt Lymphoma

Studies at this site

• A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers — Recruiting now
• A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) — Recruiting now
• A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma — Recruiting now
• FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3 — Recruiting now
• (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors — Recruiting now
• Study of SGR-1505 in Mature B-Cell Neoplasms — Recruiting now
• APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors — Recruiting now
• A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors — Running, not enrolling
• A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer — Running, not enrolling
• Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) — Running, not enrolling
• (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis — Running, not enrolling
• A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment — Completed
• Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression — Running, not enrolling
• Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) — Stopped early
• A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR) — Stopped early
• Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis — Status unconfirmed